Active material: Tamoxifen
When ATH: L02BA01
CCF: Anti-estrogen drug with antitumor activity
When CSF: 15.13.01
Manufacturer: ORION CORPORATION (Finland)
Pills round, lenticular, from white to yellow to white to creamy-yellowish brown color, с цифрой “10” на одной стороне.
| 1 tab. | |
| tamoxifen citrate | 15.2 mg, |
| that is equivalent to the content of tamoxifen | 10 mg |
30 PC. – флаконы полиэтиленовые (1) – пачки картонные.
100 PC. – флаконы полиэтиленовые (1) – пачки картонные.
Pills round, lenticular, from white to yellow to white to creamy-yellowish brown color, с цифрой “20” на одной стороне.
| 1 tab. | |
| tamoxifen citrate | 30.4 mg, |
| that is equivalent to the content of tamoxifen | 20 mg |
Excipients: corn starch, lactose monohydrate, povidone, sodium starch glycolate, magnesium stearate, Purified water.
30 PC. – флаконы полиэтиленовые (1) – пачки картонные.
100 PC. – флаконы полиэтиленовые (1) – пачки картонные.
The antitumor agent. An antiestrogen. Blocks the receptors of estrogen and thus inhibits the progression of tumor diseases, stimulated with estrogen.
Tamoxifen is metabolized in the liver, kishechno-pechenocna recycling. Return to jelchew in the form of metabolites.
Breast cancer in menopausal women, breast cancer in men after castration, kidney cancer, melanoma (contains estrogenic receptors), ovarian cancer; prostate cancer resistance to other drugs.
The mode set individually, depending on the evidence, the condition of the patient and the schemes of anticancer therapy.
From the digestive system: nausea, vomiting, increase in liver transaminases; в отдельных случаях – жировая инфильтрация печени, cholestasis, hepatitis.
CNS: редко – депрессия, dizziness, headache, optic neuritis.
On the part of the organ of vision: редко – ретинопатия, keratopathy, Cataract.
From the hematopoietic system: a rare - thrombocytopenia, leukopenia.
On the part of the endocrine system: у женщин – гиперплазия эндометрия, vaginal bleeding, tides, weight gain; у мужчин – импотенция, decreased libido.
Cardio-vascular system: swelling, thromboembolism, phlebitis.
Dermatological reactions: alopecia, rash, itch.
Other: pain in the bones and hotbeds of defeat, fever.
Tromboflebit, pregnancy, hypersensitivity to tamoksifenu.
Tamoxifen is contraindicated for use in pregnancy. If necessary, use during lactation should stop breastfeeding.
IN experimental studies teratogenic effect of tamoxifen.
Be wary when using radiation, thrombocytopenia, hypercalcemia, in patients with cataract, hyperlipidaemia.
During treatment should regularly monitor the pattern of peripheral blood (especially the number of platelets); calcium level and blood glucose; with long-term use shows the eye observation (every 3 Months).
It should not be combined with drugs, containing hormones, especially the estrogens.
In an application with drugs, influencing svertawatuyu of blood, a correction dose of tamoxifen.
IN experimental studies established carcinogenic effect of tamoxifen.
Together with the application antikoagulyantami coumarin derivatives increased risk of strengthening antikoaguljantnogo actions; с цитостатиками – возможно повышение риска тромбообразования.
Together with the application allopourinolom may gepatotoksicescoe; с аминоглутетимидом – уменьшение концентрации тамоксифена в плазме, apparently, by raising its metabolism.
Patients, receiving tamoxifen, possible prolongation of neuromuscular blockade, caused by atrakuriem.
If you are applying to dopaminergicheskogo actions may increase bromokriptina bromokriptina.
Patients, receiving tamoxifen, When applying risk threatening development of warfarin clinical situation: possible prolongation of prothrombin time, hematuria, hematoma.
If you are applying with mitomycine increases the risk of haemolytic uraemic syndrome.
May reduce the concentration in the blood plasma of tamoxifen, what, apparently, due to the induction of CYP3A4 izofermenta under the influence of rifampicin.
Estrogens may diminish the therapeutic effect of tamoxifen.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More